Philadelphia, USA, October 2, 2018 — Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the completion of its acquisition of Sherpa Clinical Packaging (Sherpa). Located in San Diego, Sherpa is a recognized provider of clinical trial materials management services and is known for its high quality, flexibility, and speed-to-market in support of investigational studies conducted around the world. Sherpa’s packaging, labeling, distribution, temperature controlled storage and returns services are highly complementary to PCI and adding this key geography strengthens PCI’s ability to support existing and new customers. PCI now has manufacturing and packaging facilities in 8 key locations across three continents and an extensive depot network to service its customers’ global needs.
San Diego, Calif. August 29, 2018 — Sherpa Clinical Packaging, a leading provider of clinical materials management services, has launched Computer-Assisted Design (CAD) services to prototype and manufacture custom packaging specifically suited to clinical trials.
“We are always looking for new ways to provide our customers with the utmost flexibility in designing and managing their clinical supplies,” says Mark Paiz, President of Sherpa. “Our latest CAD kit design service can rapidly prototype kits in a matter of hours, and produce the materials in a matter of days, instead of weeks so that our customers can meet their aggressive “first patient in” milestones.”
SAN DIEGO, Sept. 11, 2018 /PRNewswire/ — Leading clinical services provider Sherpa Clinical Packaging (Sherpa) has announced an agreement to be acquired by PCI Pharma Services (PCI). Sherpa, headquartered in San Diego, CA, provides clinical trial material management services for clinical studies phases I-IV, including packaging, labeling, distribution, storage and returns and destruction services. Sherpa’s state-of-the art facilities employ the latest cold chain technologies that include handling products requiring labeling and kitting at frozen and refrigerated conditions.
Sherpa Clinical Packaging and De:terminence Announce Initiative to Help Rare Disease Patients Climb Mountains
Sacramento and San Diego, CA, August 21, 2018 — Sherpa Clinical Packaging and De:terminence are pleased to announce a joint fundraiser to raise $50,000 to help rare disease patients conquer physically grueling challenges. All proceeds raised will be used to fund scholarships, adaptive equipment, and customized training to prepare rare disease patients to climb mountains, participate in triathlons and marathons across the US.
“Being told that you have a disease for which there is no cure is crushing,” says Sean Baumstark, founder of De:terminence and Friedreich’s Ataxia patient. “I founded De:terminence to remind other rare disease patients that life is still worth living right now, not only if a cure is found. De:terminence provides specialized practical and emotional support rare disease patients need to accomplish amazing physical feats.”
August 21-22, 2018: Outsourced Pharma – San Diego, California
September 6, 2018: Hynes Convention Center – Boston, MA
September 11th, 2018: BioCom – Temperature Controlled Distribution of Biologics – San Diego, California
Osteoarthritis affects around 30 million Americans, causing pain and severe disability. Unfortunately, there are few treatments. Many rely on over-the-counter analgesics to manage their pain. Some ultimately opt for joint replacement surgery.
To better help patients, OrthoTrophix is developing a peptide drug designed to regenerate cartilage. The company hopes this approach will restore function.
It is up to pharmaceutical companies sponsoring clinical trials in the EU to have comprehensive control of their supply chain. This ensures the quality of their drug supply is not compromised and patients are not inadvertently administered counterfeit or falsified drugs.
Article by Sue Mann, founder and Managing Director, Sue Mann Consultancy Ltd
The QP process is a necessary process that every sponsor company wishing to undertake trials in, or move product through the European Union must undergo. When faced with this process, many companies are unsure as to what to expect. Here are the top ten things that sponsor companies should know about the QP Process.